83 results about "Hematocrit" patented technology

The embodiment of the invention provides a continuous blood oxygen monitoring system in extracorporeal circulation and a control method thereof. The continuous blood oxygen monitoring system comprises a vein sensor, an artery sensor, a blood flow sensor, an oxygen sensor, a carbon dioxide sensor, a controller and a display, the vein sensor monitors the vein blood oxygen saturation degree; the artery sensor monitors arterial oxygen saturation and hematocrit; the blood flow sensor monitors the blood flow of the artery pipeline; the oxygen sensor monitors the oxygen concentration of the oxygenator; the carbon dioxide sensor monitors the carbon dioxide concentration of the oxygenator; the display provides an interaction control, responds to a trigger operation acting on the interaction control, sends an interaction instruction to the controller, and updates information displayed in an interaction interface according to the control of the controller; the controller receives the interaction instruction and executes processing corresponding to the interaction instruction; the processing includes controlling display information of the display; the display information comprises information corresponding to the monitoring parameters. The scheme ensures the safety and effectiveness of the treatment process.

The invention relates to the technical field of intraoperative intelligent monitoring, and particularly discloses a spinal canal debonding method and system for real-time state evaluation, and the method comprises the steps: collecting neural structure microcirculation blood flow data in real time through integrating a micro-sensing unit at a working end part of a surgical instrument, and extracting blood flow oscillation frequency and capillary hematocrit parameters; performing multi-scale signal decomposition on the blood flow oscillation frequency to obtain an energy distribution parameter, and performing dynamic mode recognition on the hematocrit data to obtain a main variation characteristic value; fusing the two characteristic parameters to generate a nervous tissue vitality index; inputting the index into a pre-trained neural network for time sequence feature analysis, and outputting a graded ischemia risk early warning signal; the operation rhythm is automatically adjusted through a decision tree control mechanism based on the early warning signal, and self-adaptive regulation and control according to the state of the nervous tissue are achieved; the technical problem that the risk of neural ischemia cannot be monitored in real time in a traditional spinal canal release operation is solved, and occult nerve injury caused by asymptomatic neural ischemia can be prevented.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

Disclosed in the present application are an HCT prediction method and system, a device, and a medium. Photons in a photon group are emitted into an extracorporeal circulation blood model so that the photons are reflected, scattered, or absorbed during movement. The extracorporeal circulation blood model is a model constructed on the basis of the thickness of an extracorporeal circulation tube, the thickness of the blood, and the distance from a light source generator to a detector. Light intensity data corresponding to photons reaching the detector are acquired. The acquired light intensity data are input into a prediction model to obtain a hematocrit (HCT) prediction value. The prediction model is a model constructed on the basis of a BP neural network and the relationship between light intensity and HCT. The prediction model combining simulation and neural network increases the data volume, achieves continuous non-invasive estimation of HCT by means of algorithm model optimization, and improves the accuracy of HCT prediction.

There is disclosed a vital sign measuring device and method for obtaining an indication of a person's blood pressure via the person's finger by means of an inflatable measurement bladder adapted to contact only a portion of an underside of a finger defining a finger pad. A structure or other implement applies a downward force on a top portion of the finger opposite the finger pad. Blood pressure may be determined without the use of any electromagnetic radiation, such as miniature dynamic light sensing (mDLS). Apparatuses and methods for obtaining an indication of other vital signs, including hematocrit and total protein, are also disclosed.

The invention is applicable to the field of in vitro diagnostic equipment, and discloses sample analysis equipment and a control method of the sample analysis equipment, the sample analysis equipment comprises a sample measuring device, a camera device, a display device and a control device, the display device is used for displaying a first interface, and the control device is used for controlling the camera device. The first interface is used for displaying a first target image obtained by shooting the sample container according to the camera device; and displaying a second target image obtained by shooting the sample container according to the camera device, information used for representing a hematocrit detection result of the blood sample, information used for representing a clot detection result of the blood sample, and information used for representing a liquid amount detection result of the blood sample. The information is at least one of information for representing a hemolysis detection result of the blood sample, information for representing a jaundice detection result of the blood sample, and information for representing a lipid detection result of the blood sample. According to the invention, the efficiency and intuition of blood sample quality auditing are improved.

The method for monitoring parameters of a patient during surgery with extracorporeal circulation serves to estimate the presence of AKI risk and comprises calculating a dynamic global index of AKI risk as a logistic regression deriving from a static AKI risk index and a dynamic index of AKI risk. The value and / or the time trend of such global index of AKI risk can be advantageously displayed on a monitor during the surgery. The dynamic AKI risk index is calculated at least on the basis of the extracorporeal circulation time, the minimum level of oxygen supply and the exposure time to oxygen supply below a critical threshold which are measured or determined repeatedly during surgery. Preferably, the dynamic AKI risk index is also calculated on the basis of the minimum mean arterial pressure during surgery and / or the maximum concentration of lactate in the blood during surgery and / or the minimum hematocrit during surgery and / or the fact that the patient has been subjected to transfusion(s) during the extracorporeal circulation.

A blood separation device includes a pump system, a separator, and a controller. The controller is programmed to execute a blood separation procedure including a red blood cell collection stage in which blood is conveyed into the separator, red blood cells are separated from the blood in the separator, and the separated red blood cells are conveyed from the separator into a collection container. The red blood cell collection stage is ended when a target volume of blood has been separated in the separator. The controller then determines a percentage of the red blood cells from the target volume of blood that have been collected in the collection container based on the volume of red blood cells and the hematocrit of the fluid in the collection container, a volumetric flow rate of pure red blood cells in the blood conveyed into the separator, and the procedure time.

The invention discloses an application of a natural product WithangatinA in preparation of erythroleukemia induced differentiation treatment drugs, the natural product WithangatinA promotes HEL and K562 cells to be transformed from malignant proliferative cells to normal megakaryocytes by inducing the cell particle size to become larger and significantly increasing multinuclear megakaryocytes and promoting expression of surface labeled molecules differentiated from megakaryocytes at the same time, and the erythroleukemia induced differentiation treatment drugs are obtained. The effect of resisting erythroleukemia is achieved. After the natural product Withangulin A is adopted for treatment, the size and the weight of the spleen of a leukemia mouse can be remarkably reduced, the hematocrit and the platelet number of the mouse are remarkably increased, in addition, treatment of the natural product Withangulin A has no obvious influence on the weight of the mouse, and the safety is high. In-vivo research shows that the medicine can induce megakaryocyte differentiation of erythroleukemia in a mouse body, the effect of resisting erythroleukemia is achieved, and a research basis is provided for development of differentiation treatment medicines of erythroleukemia.

A system includes: a dialysis system configured to provide a dialysis treatment for a patient; an optical monitoring system in communication with the dialysis system, wherein the optical monitoring system is configured to obtain measurements of the patient's hematocrit, oxygen saturation and / or blood volume change during the dialysis treatment, wherein the measurements are indicative of a double pool refill rate for the patient during the dialysis treatment; and a massaging system in communication with the dialysis system, wherein the massaging system is configured to provide massaging for the patient during the dialysis treatment, wherein providing massaging for the patient includes running a massage sequence taking into account the measurements obtained by the optical monitoring system.

The present invention discloses a method for separating components after centrifugation of blood cells, which belongs to the field of medical technology. It is achieved by utilizing the photosensitivity of the sensor and the difference in relative light absorption of each component after blood cell separation; after centrifugation, the blood cells are separated into a red blood cell layer, a buffy coat, and platelet-poor plasma. When each phase passes through the sensor, the relative light absorption characteristics of each phase are different, thereby accurately monitoring the blood layer. When each phase of the present invention passes through the sensor, the light absorption characteristics of the blood components are different, and accurate blood layer monitoring is performed based on this principle. The composition of the prepared product phase and subphase can be changed by changing the preset hematocrit. The sensor pipeline part that matches the sensor is a flat pipeline with a cross-section that is close to a large and flat rounded rectangle. It is made of a material with good light transmittance such as polycarbonate, so that light of different wavelengths emitted by the LED light emitter can pass through the flat pipeline vertically and be received by the light receiver.

The invention discloses a biological chip sampling quantitative correction method and a biological chip. A blood filtering stop recognition line, a quantitative recognition line and a quantitative start recognition line are sequentially arranged on a quantitative tube of the biological chip, the blood filtering stop recognition line is arranged close to a quantitative inlet, the quantitative start recognition line is arranged close to a quantitative outlet, and the quantitative recognition line is located between the blood filtering stop recognition line and the quantitative start recognition line. When the lower liquid level of the sample reaches the blood filtering stop identification line, stopping the blood filtering action; when the lower liquid level of the sample reaches a quantitative starting identification line, pre-pressing the sample to enable liquid drops to grow at a quantitative outlet, then adding the sample for detection according to a unified quantitative volume or other quantitative volumes according to the relationship between the upper liquid level of the sample and the quantitative identification line, if adding the sample for detection according to the other quantitative volumes, multiplying a detection result by a corresponding coefficient, the corresponding coefficient is equal to the ratio of the unified quantitative volume to the remaining quantitative volumes. The quantitative detection success rate of samples with the same volume and different hematocrites reaches 100% by adopting the method.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

A method of analyzing a blood sample from a subject includes loading the blood sample into a single chamber; acquiring, via an imaging system, a stack of serial focal plane images of the blood sample from a plurality of fields of view of the chamber; creating a virtual three dimensional image of the blood sample from selected ones of the stacks of serial focal plane images; and analyzing the virtual three dimensional image to identify blood formed elements within the blood sample. Identifying blood formed elements within the blood sample may include identifying a type and amount of white blood cells, and / or identifying an amount of red blood cells and / or hematocrit, and / or identifying an amount of platelets. Identifying blood formed elements within the blood sample may include determining numbers and percentage by volume in the blood sample of one or more types of white blood cells.

Provided is a means for quantitative analysis of an analyte including mycophenolic acid and one or more other immunosuppressants using a whole blood fraction without requiring separation of a blood sample. One embodiment of the present invention relates to a method for quantifying an analyte including mycophenolic acid and one or more other immunosuppressants in a blood sample of a subject, the method comprising: an analyte concentration measurement step for measuring the concentration of the analyte; measuring the concentration of an analyte including mycophenolic acid and one or more other immunosuppressants in the whole blood fraction of the blood sample; a hematocrit value acquisition step for acquiring the hematocrit value of the target blood sample; and a mycophenolic acid concentration conversion step for converting the concentration of mycophenolic acid in the whole blood fraction of the blood sample into the concentration of mycophenolic acid in the plasma fraction of the blood sample on the basis of the hematocrit value.

The invention provides a blood sampling system and a blood sampling detection method for a blood station, and the method comprises the steps: carrying out the blood coagulation test of a first blood sample, and extracting a backscattering signal after the turbulence phenomenon of the blood; decomposing the backscattering signal into a linear component signal and a nonlinear component signal; extracting the shrinkage rate of fibrin in the first blood sample from all the linear component signals, determining the flow characteristic of the first blood sample through all the nonlinear component signals, and determining the agglomeration index of red blood cells in the uncoagulated blood of the target user by combining the shrinkage rate and the flow characteristic; and correcting the hematocrit in the blood of the target user based on the agglomeration index, and evaluating the blood quality of the target user through the corrected hematocrit. By adopting the scheme provided by the invention, the hematocrit can be subjected to confidence detection under the influence of red blood cell agglomeration.

A system for washing red blood cells, comprising a separator configured to separate a quantity of blood into concentrated red blood cells having a hematocrit of at least 60% and a volume of 150-250 mL, and a supernatant component. The system comprises a flow controller configured to remove the supernatant component to provide an initial red blood cell concentrate; combine 50-500 mL of an additive solution with the red blood cell concentrate to provide an intermediate red blood cell product intended for storage for 42 days or less; and wash the intermediate red blood cell product with a washing solution.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

The invention provides a blood glucose evaluation method based on hematocrit compensation and a related device, and the method comprises the steps: obtaining blood glucose reaction current and erythrocyte backlog background current at equal time intervals within the effective reaction time of test paper and a blood sample; determining a tap adjustment coefficient and a hematocrit compensation coefficient corresponding to the amplification voltage value and the erythrocyte backlog background current according to the blood glucose reaction current and the erythrocyte backlog background current; performing two-dimensional compensation calculation on the amplified voltage value to obtain a corrected voltage value; determining a final voltage value by adopting a weighted integral calculation mode according to the corrected voltage value; according to the final voltage value and a preset blood glucose concentration mapping function, the blood glucose value for hematocrit compensation is determined, the influence of multi-dimensional factors in the blood glucose reaction process can be comprehensively considered, the negative influence of interference factors such as hematocrit on the detection result is effectively eliminated, and the accuracy and reliability of blood glucose detection are remarkably improved.

The utility model relates to medical equipment technical field discloses a kind of platelet-rich plasma separators, comprising: round plate, the outer surface of the round plate is fixedly installed with limit block.This kind of platelet-rich plasma separator, due to the design of movement mechanism, reach the flexible adjustment effect of centrifugal radius without replacing centrifugal cup, can be according to different patient blood viscosity, hematocrit and other indexes, accurately control centrifugal force, avoid platelet residue or excessive activation, significantly improve platelet-rich plasma preparation quality and biological activity.Discard the cumbersome operation of traditional replacement centrifugal cup, substantially improve operation efficiency, while reducing the mismatch risk caused by frequent replacement of spare parts, reduce the operation burden of medical staff, reduce equipment spare parts procurement cost and management difficulty, effectively improve the versatility and utilization of equipment, reduce hospital equipment procurement and maintenance cost.

The application discloses a multi-association coagulation time detection instrument and reagent card, and relates to the field of medical devices.The instrument comprises an instrument body, a reagent card channel for reagent card insertion, a first sensor and a second sensor arranged on the instrument body, the first sensor being used for detecting one end of a test channel on the reagent card, and the second sensor being used for detecting a waste liquid channel of the reagent card; a driving module, which is in communication with the waste liquid channel and the test channel respectively; and a control processing unit, which is in signal connection with the driving module, the first sensor and the second sensor respectively.After the above-mentioned instrument is used, a plurality of coagulation items can be tested at a time, each test channel can individually and accurately quantify a sample, and the blood sample and the reagent can be effectively mixed, so that the sample in the test channel can be prevented from being sucked into an air path, the waste liquid sample in the waste liquid channel can be prevented from flowing back, whether the added sample is excessive or insufficient can be detected, and the hematocrit of blood can be accurately detected.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices may include the use of an RBC flocculant, for example polyDADMAC, and an approximate blood hematocrit from the type of animal blood being evaluated, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal blood hematocrit, and a calculated RBC packing ratio “η” value for the collection device. A collection device with a BIP is disclosed. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Methods and systems are disclosed for assisting with the management of anemia in a patient. In some examples, the method includes accessing patient parameters associated with the patient, wherein the patient parameters include an aligned hemoglobin time series for the patient generated from multiple measurement sources. The method then includes accessing a physiology-based model and adapting the physiology-based model into a patient specific model that predicts future hemoglobin levels for the patient based on one or more erythropoiesis-stimulating agent (ESA) dosing regimens, wherein adapting the physiology-based model to the patient specific model utilizes the patient parameters, and generates estimates of patient-specific physiological characteristics. The method then includes running simulations with the patient specific model and determining a recommended ESA dose. The recommended ESA dose that the model predicts will cause either or both of the patient's hematocrit or hemoglobin concentration to reach a desired range within a specified time frame.

The invention relates to a system and a method for optimizing plasma collection volume. A plasma retrieval system and a method for operating a plasma retrieval system are provided by which the volume / weight of collected anticoagulant plasma is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma extraction process having a plurality of collection phases, after which a re-infusion cycle, in which concentrated red blood cells are returned to the donor, the volume of the plasma product to be collected is calculated before each collection cycle begins to account for an increased hematocrit of the donor, and the volume of the plasma product to be collected is calculated before each collection cycle begins. Thus, the total volume of the plasma product to be collected during the plasma extraction process is larger.

A method for collecting blood components using a medical system, the method comprising: receiving data associated with a subject by the medical system, the data associated with the subject including the subject's initial hematocrit value; determining the amount of subject-specific pure component to be collected by the medical system, the amount of subject-specific pure component to be collected by the medical system being determined using the subject's hematocrit value, the subject's total blood volume, and a target change in the hematocrit value; and performing a component collection process using the medical system to collect the determined amount of subject-specific pure component.

The present application relates to the technical field of pattern recognition, in particular to a multi-type blood glucose test paper recognition system, comprising four modules of feature perception, intelligent identification, excitation execution and compensation calculation, first, collecting high-frequency impedance phase sequence, charge-discharge relaxation time constant and sample transient surge signal through intelligent sensor, using recursive graph quantitative analysis to extract coupling feature vector; then, projecting the coupling feature vector to the attribute subspace of the preset matrix library, identifying the test paper reaction mediator potential interval, enzyme layer load abundance and hematocrit non-linear coefficient, and dynamically synthesizing the target excitation waveform containing the ladder-shaped pre-polarization segment and the load modulation sampling segment; then, driving the biochemical reaction according to the identification result to capture the Faraday steady-state response current; finally, using the weight matrix to execute space charge layer correction and diffusion flux gain adjustment, and outputting the detection result. The present application realizes accurate detection of heterogeneous test paper through multi-dimensional feature identification.

The invention discloses a preparation method of concentrated red blood cells from umbilical cord blood, and belongs to the field of biomedical engineering.According to the technical scheme, the preparation method comprises the following steps that umbilical cord blood is collected, whole umbilical cord blood is directly connected with a triple bag and then subjected to 600 * g centrifugation for 7 min at the temperature of 4 DEG C, umbilical cord blood plasma, umbilical cord blood mononuclear cells and suspended red blood cells are separated out, and the umbilical cord blood mononuclear cells and the suspended red blood cells are collected; and continuously centrifuging the obtained suspension red blood cells at 4 DEG C for 7min by 5000 * g, further concentrating the red blood cells, and removing upper plasma to obtain the concentrated red blood cells of the umbilical cord blood. According to the invention, 6% hydroxyethyl starch which is conventionally used is not added during preparation, but after technical optimization, aggregation and precipitation of red blood cells due to structural change are avoided, and the oxygen storage and transportation functions of the red blood cells are reserved, so that the red blood cells can be used as a red blood cell resource source. The hematocrit of the concentrated red blood cells obtained by the method is higher than 80%, the hemoglobin content recovery rate is higher than 55%, and the concentrated red blood cells can be used for autologous retransfusion of red blood cells during anemia of neonates, especially premature infants.